about us
“The greatest need we have today in the human cancer problem, except for a universal cure, is a method for detecting cancer before there are any clinical signs or symptoms.”
Sidney Farber, M.D.
Father of modern chemotherapy
November 1962
pioneering the detection of early cancer
Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. Incubated within Flagship Pioneering for three years before launching in 2021, Harbinger combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test.
A harbinger is a “forerunner, that which precedes and gives notice of the coming of another.” We not only are working to identify the harbinger – the biological programs present in the earliest forms of cancer – but seek to be the harbinger, to be the forerunner which will usher in the future of healthcare.
At Harbinger, we intend to lead in shaping this future – creating a proactive paradigm so that people can live cancer-free for longer, adding years to life and life to years. We envision a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies.
Our answer to the problem of late cancer detection and unacceptable patient prognoses starts with our proprietary solutions for the future of cancer pre-emption. Beginning with blood-based tests, we will enable cancer detection before it is visible. By identifying biological programs rooted in cancer's origins, we can enable identification of early stage and pre-disease. Through this new pathway for cancer diagnosis and early therapeutic interventions, Harbinger Health has the potential to fundamentally change cancer care, for everyone.
Dymeka Harrison
Dymeka Harrison, M.B.A., serves as Chief Commercial Officer at Harbinger Health. She has an extensive background in the diagnostics industry, bringing over 30 years of experience to her role. Dymeka directs the Company’s global, clinical and commercial strategy and partnerships, as well as the introduction of cancer detection products and findings. Prior to joining Harbinger, Dymeka served as Chief Commercial Officer for Foundation Medicine where she played a critical part in diversifying the markets in which the company operated, implementing successful growth strategies and increasing brand recognition.
Throughout her career, Dymeka managed and restructured sales teams across her professional portfolio while initiating promotions in regional and global markets. She was at the forefront of optimizing payer engagement as well as driving top line sales and margins. Dymeka has managed multi-million- and billion-dollar initiatives while leading the charge from ideation, innovation, value creation and branding. Her knowledge in science and medicine stems from over 14 years at Abbott Diagnostics. From her tenure at Abbott, QIAGEN and Thermo Fisher Scientific, she became well rounded in specialties and areas such as hematology, life sciences, infectious disease and molecular diagnostics.
Dymeka holds an M.B.A. from Georgia State University and a B.S. in Manufacturing and Engineering from North Carolina Agricultural and Technical State University.
